Chapter 44: Renowned Across the World Once More

Page 1 of 3

Recently, at the Affiliated Hospital of Yanhuang University in Huaxia, the world’s first successfully cured AIDS patient was discharged. It is reported that Zhou Lin, the patient, had previously been given just two weeks to live, but now has made a full recovery and returned to a normal life.

This case marks the end of AIDS as an invincible demon and signals a new chapter in the history of human bioscience. The innovative approach of fighting poison with poison now holds promise for tackling other diseases long deemed insurmountable, such as cancer.

Li Fu, a bioscientist from Huaxia and a third-year undergraduate student at just 21 years old, is now a strong contender to become the youngest recipient in the history of the Nobel Prize in Science, potentially breaking Lawrence Bragg’s record set at age 25 in 1915.

The most influential television station in the United Kingdom dedicated several minutes during prime time news to report in detail on this monumental moment in human bioscience.

...

Good evening, viewers. Welcome to the news broadcast. Today’s headlines: Huaxia’s own bioscientist Li Fu has successfully developed a drug capable of curing AIDS. Today, the first fully cured patient, Zhou Lin, was discharged from hospital. This signals another human victory in the fight against disease, making AIDS no longer an untreatable illness. Over sixty million AIDS patients worldwide may now see hope for a new life.

The ancient wisdom of fighting poison with poison shines once again in the new era, and it also demonstrates that Huaxia’s bioscience technology now leads the world. In this emerging field of biological viruses, only Huaxia’s scientists have achieved such feats, and there is hope that this technology will be applied to cure even more diseases in the future.

This is a great moment in human history, a proud moment for the descendants of Yan and Huang, and the rich fruit of our nation’s long-standing commitment to technological advancement...

Huaxia’s most significant and authoritative news program, airing at 7:30 in the evening, also spent a full five minutes celebrating this monumental event, with such praise that it almost seemed exaggerated.

With Zhou Lin’s successful cure, the news spread across the globe in an instant. Unsurprisingly, it immediately became the top story on various media outlets. For decades, AIDS has plagued humanity, tormenting tens of millions worldwide, with millions dying from it every year.

Moreover, since the first case was discovered in the United States in 1981, AIDS has spread rapidly across the globe, becoming increasingly uncontrollable, with the numbers of new infections and deaths soaring annually.

Now, all concerns about AIDS have vanished. Major media outlets worldwide are giving extensive coverage, and Li Fu’s name is being repeated everywhere. Practically the whole world now knows of this young bioscientist from Huaxia.

Time magazine even announced on the very same day that Li Fu had been selected as one of the most influential people of 2017, one of the hundred greatest scientists in human history, and among the top 100 outstanding young people worldwide...

Page 2 of 3

...

In New York, at Pfizer Pharmaceutical Company—although many may not have heard of this company, anyone in the medical field knows it as the undisputed pharmaceutical giant and the world’s leading pharmaceutical enterprise.

With over 150 years of history, Pfizer is a global titan with an unprecedented scale, a wide range of therapeutic fields, and an extensive product line. Its innovative products are marketed in over 150 countries and regions worldwide. Pfizer possesses the world’s most advanced production facilities and testing technologies, and its cumulative investment in Huaxia alone exceeds $500 million.

Currently, Pfizer has launched more than forty innovative medical products in China, collectively dominating the fields of cardiology, endocrinology, neurology, infectious diseases, arthritis and inflammation, urology, ophthalmology, and oncology.

At Pfizer’s global headquarters, CEO Robert was presiding over a high-level meeting attended by all of Pfizer’s major shareholders.

“There are currently over sixty million AIDS patients worldwide, and the disease is spreading rapidly across the globe. Each year, the number of new infections rises sharply...” The enormous screen in the conference room displayed global statistics on AIDS.

“Gentlemen, as you can see, the AIDS sector is a vast cake. Whoever makes the breakthrough first will feast on this cake.”

“Just imagine, a market of over sixty million people, expanding rapidly each year. By 2020, this market could swell to a terrifying one hundred million people.”

“A market of one hundred million lives, utterly irreplaceable, is enough to double our company’s performance and the fortunes of everyone here.”

Robert spoke with compelling rhetoric. In his eyes, patients were simply a market; without patients, there were no profits. The number of deaths from AIDS was of no concern to him.

“Mr. Robert, we know the method to manufacture this drug is in the hands of Li Fu from Huaxia. What support do you need from us to acquire this method from him?” asked Harrison, Pfizer’s largest shareholder, unable to resist such temptation and smiling at Robert.

Page 3 of 3

“I need you all to authorize me to deploy a significant sum. Part of it will fund our own labs in researching this new bioscience technology, and the other part will be used to acquire it from Huaxia.”

In this country of professional managers, strict regulations govern management practices. For major corporate decisions, Robert needed the board’s authorization and support from the shareholders; without it, his actions would be illegal and his career over.

“So, Mr. Robert, how much funding do you want us to authorize?” Harrison smiled slightly, exchanged glances with the other shareholders, and asked.

“The more, the better, but at the very least, not less than one billion dollars.”

Robert calmly stated the figure. One billion dollars—a vast sum even in this country, equivalent to more than six billion in local currency.

“One billion dollars is no small sum,” Harrison remarked, and the shareholders all furrowed their brows, rapidly weighing whether to authorize such an amount.

Meanwhile, major pharmaceutical companies around the world—Pfizer, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck, Novartis, Bayer, and others—were all scrambling to dispatch teams to Huaxia, each armed with vast sums, all eager to obtain this groundbreaking AIDS treatment technology from Huaxia.